Investor Presentaiton
33
Key data and progress
Probability of Survival (%
Project information
HLX99: "First-In-Class" anti-ALS/PD Drug Candidate
Indication
Amyotrophic Lateral Sclerosis (ALS);
Parkinson's disease (PD)
• Entity
Patent filed. IND to be approved in China
in 2024 H1
MOA
Polypharmacology, the molecule has a variety
of biological activities including but not limited
to modulation of neurotransmitters, inhibition of
oxidative stress, regulation of body metabolism,
modulation of immune disorders, and
modulation of gut microbiota
MOA of the Anti-Neurodegenerative Diseases (NDDs) Drug Candidate HLX99
HLX99
Polypharmacological
activities
1. HLX99 prolongs the survival of ALS transgenic mice, improves the behavior
of this model mice and decreases the neuronal damage marker NFL in blood
100
50
100
Survival Proportions
HLX99
Model
110
120
130
Days
Time (s)
80
60-
40-
20-
Grid Test
NC'
Model
AMX0035
HLX99(334mpk)
HLX99(496mpk)
pg/mL
2000
1500-
1000-
500-
0-
NC
Serum NFL
Model
AMX0035
HLX99(334mpk)
HLX99(496mpk)
Grip (g)
Damage
protection
Immune
modulation
Metabolic
regulation
Microbiota
regulation
2. HLX99 ameliorates MPTP-induced decrease in grip
strength and loss of dopamine neurons in PD mice
280-
260-
240-
220-
200-
180.
***
Sham
model
L-DOPA
HLX99
2024 Henlius.
TH Staining in Substantia nigra
Neuron
damage
Metabolic
disorders
NDDs
Neuro-
inflammation
Bacterial
imbalance
3. HLX99 improves fault step
rate in 6-OHDA PD model
Fault step rate (%)
Sham
Model
0
HLX99
L-Dopa
(334mpk)
HLX99
(496mpk)
20-
15-
10.
5
HLX99
Sham
Model
Itraphylline
2 HenliusView entire presentation